Key takeaways
Skyrizi (risankizumab) and Bimzelx (bimekizumab) are both medications used to treat moderate-to-severe plaque psoriasis and psoriatic arthritis in adults and belong to the interleukin antagonist medication class. However, they have several differences. Skyrizi is also FDA-approved for ulcerative colitis and Crohn's disease, while Bimzelx is approved for non-radiographic axial spondyloarthritis, ankylosing spondylitis, and hidradenitis suppurativa. Skyrizi is administered as an injection every 2 or 3 months after initial doses, whereas Bimzelx is injected every month initially and then every other month. Skyrizi is available as a prefilled syringe, pen, and On-Body Injector, while Bimzelx comes as prefilled autoinjectors and syringes. Common side effects of Skyrizi include joint pain and a higher risk of infections, while Bimzelx may cause runny nose, cough, and oral thrush. Both medications require caution with live vaccines due to their effects on the immune system.
